(Total Views: 614)
Posted On: 04/02/2024 10:14:50 PM
Post# of 154938
1/13/2021 cancers patent covers " an effective amount ".
3. The method according to claim 1, wherein the cancer comprises CCR5- positive melanoma, brain cancer, glioblastoma, throat cancer, lung cancer, stomach cancer, colon cancer, colon carcinoma, breast cancer, testicular cancer, ovarian cancer, uterine cancer, pancreatic cancer, bladder cancer, esophageal cancer, appendix cancer, or prostate cancer."
" Embodiments include dosages in amounts ranging from about 175 mg to about 1,400 mg, including dosage forms delivering certain amounts of the CCR5 binding agent such as 175 mg, 350 mg, 525 mg, 700 mg, 875 mg, 1050 mg, 1,225 mg, and 1,400 mg."
https://patents.google.com/patent/WO2021146323A1/en
& was just printed internationally on 3/4/2024 :
https://patentscope.wipo.int/search/docs2/ias...5Ajkg9umM8
My novice medical guess is that other MAB's will once again, need to find alternate routes as trials prove up the patents value.
3. The method according to claim 1, wherein the cancer comprises CCR5- positive melanoma, brain cancer, glioblastoma, throat cancer, lung cancer, stomach cancer, colon cancer, colon carcinoma, breast cancer, testicular cancer, ovarian cancer, uterine cancer, pancreatic cancer, bladder cancer, esophageal cancer, appendix cancer, or prostate cancer."
" Embodiments include dosages in amounts ranging from about 175 mg to about 1,400 mg, including dosage forms delivering certain amounts of the CCR5 binding agent such as 175 mg, 350 mg, 525 mg, 700 mg, 875 mg, 1050 mg, 1,225 mg, and 1,400 mg."
https://patents.google.com/patent/WO2021146323A1/en
& was just printed internationally on 3/4/2024 :
https://patentscope.wipo.int/search/docs2/ias...5Ajkg9umM8
My novice medical guess is that other MAB's will once again, need to find alternate routes as trials prove up the patents value.
(5)
(0)
